Showing results (341-350 of 457) with videos related to
Sort By:
Pageof 46
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trialRobert J Motzer, Dmitry Nosov, Timothy Eisen, et al.European Urology|June 4, 2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only DiseaseJoaquim Bellmunt, Thomas Powles, Se Hoon Park, et al.European Urology|April 30, 2023
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 TrialPetros Grivas, Se Hoon Park, Eric Voog, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genesChun-Fang Xu, Nan X Bing, Howard A Ball, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.European Journal of Cancer (Oxford, England : 1990)|June 30, 2026
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trialKarim Fizazi, Matthew R Smith, Maha Hussain, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T Tagawa, Arjun V Balar, Daniel P Petrylak, et al.ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2026
A phase I dose-escalation/expansion study of fractionated-dose and multiple cycle anti-PSMA-targeted alpha emitter 225Ac-J591 in patients with prostate cancerScott T Tagawa, Charlene Thomas, Abdul Baseet Arham, et al.The Lancet. Oncology|September 23, 2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trialCora N Sternberg, Daniel Castellano, Gedske Daugaard, et al.Pageof 46